comparemela.com
Home
Live Updates
Myeloproliferative Neoplasms - Breaking News
Pages:
6
7
8
9
10
11
12
Latest Breaking News On - Myeloproliferative neoplasms - Page 5 : comparemela.com
Prognosis and Treatment Strategies in Myelofibrosis: Risk Assessment and Therapeutic Goals
Aaron Gerds, MD, MS, explores myelofibrosis risk assessment, treatment goals, and therapeutic strategies, including JAK (Janus kinase inhibitors) inhibitors and transplant considerations.
Aaron gerds
Dynamic international prognostic scoring system
Merit based incentive payment system
Myelofibrosis secondary
Prognostic model
Myeloproliferative neoplasms
Clinical features
Quality of life
Cytokine mediated symptoms
Chronic illness
Disease burden
Patient characteristics
Jak inhibitors
Nccn guidelines
Anemia intervention
Category recommendations
Hobbs Highlights Key Research in Hematologic Malignancies at the 2023 ASH Annual Meeting
Gabriela Hobbs, MD, discusses the significance of key research across myeloproliferative neoplasms from the 2023 ASH Annual Meeting.
Gabriela hobbs
Ruxolitinib jakafi
News network
Myeloproliferative neoplasms
MDS Research Expands Treatment Options Across Disease Subsets
Talha Badar, MBBS, MD, discusses myelodysplastic syndrome risk stratification and the FDA approval of luspatercept for patients with this disease.
United states
Talha badar
International prognostic scoring system
Mayo clinic
Revised international prognostic scoring system
Myeloproliferative neoplasms
Fda approval
Understanding Myelofibrosis: Disease Spectrum and Impact on Quality of Life
Aaron Gerds, MD, MS, compares myelofibrosis with other myeloproliferative neoplasms, explores its prevalence in the US, and reviews the diverse clinical presentations and the impact on patients’ quality of life.
United states
Aaron gerds
Myeloproliferative neoplasms
Clinical features
Quality of life
Cytokine mediated symptoms
Chronic illness
Disease burden
Patient characteristics
Jak inhibitors
Nccn guidelines
Anemia intervention
Category recommendations
Evidence blocks
Symptomatic high risk
Oral HMAs May Provide Safer and More Effective Treatment Options for MDS
Guillermo Garcia-Manero, MD, spotlights the evolution of oral azacitidine- and decitabine-based regimens for MDS.
United states
Guillermo garcia manero
Translational research
International prognostic scoring system
Division of cancer medicine
University of texas md anderson cancer center
Department of leukemia
Faculty senate
Myelodysplastic syndromes
Cancer medicine
Cancer center
Revised international prognostic scoring system
Myeloproliferative neoplasms
Oral regimens
Decitabine plus cedazuridine
Azacitidine plus cedazuridine
vimarsana © 2020. All Rights Reserved.